Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 4856-4865

  Kohne C H ^a   Van Cutsem, E ^b   Wils, J ^b   Bokemeyer, C ^b   El Serafi, M ^b   Lutz, M P ^b   Lorenz, M ^b   Reichardt, P ^b   Ruckle Lanz H ^b   Frickhofen, N ^b   Fuchs, R ^b   Mergenthaler, H G ^b   Langenbuch, T ^b   Vanhoefer, U ^b   Rougier, P ^b   Voigtmann, R ^b   Muller L ^b   Genicot, B ^b   Anak, O ^b   Nordlinger, B ^b  

^a KLINIKUM OLDENBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ATROPINE; BEVACIZUMAB; CETUXIMAB; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; OXALIPLATIN; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; ORAL REHYDRATION THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24644432555     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.546     Document Type: Article

References (36)

1. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80: 1179-1187, 1997
2. Mini E, Trave F, Rustum YM, et al: Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 47: 1-19, 1990
3. Meta-Analysis Group in Cancer: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
4. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
5. Köhne C-H, Schoffski P, Wilke H, et al: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16:418-426, 1998
6. Köhne C-H, Wils J, Lorenz M, et al: Randomized phase III study of high dose 5-fluorouracil given as a weekly 24 hour infusion with or without leucovorin versus bolus 5-fluorouracil plus leucovorin in advanced colorectal cancer: EORTC Gastrointestinal Group Study 40952. J Clin Oncol 21:3721-3728, 2003
7. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer: CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11:909-913, 1993
8. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
9. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
10. Saltz L: Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. Oncology 14:47-50, 2000 (suppl 14)
11. Firvida JL, Irigoyen A, Vazquez-Estevez S, et al: Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 91:704-711, 2001
12. Ychou M, Raoul JL, Desseigne F, et al: High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 50:383-391, 2002
13. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
14. Pilot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15: 2910-2919, 1997
15. Freyer G, Rougier P, Bugat R, et al: Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure: CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 83:431-437, 2000
16. Michael M, Hedley D, Oza A, et al: The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: Its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer 2:93-101, 2002
17. Tsavaris NB, Polyzos A, Gennatas K, et al: Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination. Chemotherapy 48:94-99, 2002
18. Vieitez JM, Carrasco J, Esteban E, et al: Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with fluorouracil-based chemotherapy: A study to determine recommendable therapeutic dosage. Am J Clin Oncol 26:107-111, 2003
19. Cassinello J, Lopez-Alvarez P, Martinez-Guisado A, et al: Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer. Med Oncol 20:37-43, 2003
20. Fuchs CS, Moore MR, Harker G, et al: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-814, 2003
21. Vanhoefer U, Harstrick A, Achterrath W, et al: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 19:1501-1518, 2001
22. Cunningham D, Maroun J, Vanhoefer U, et al: Optimizing the use of irinotecan in colorectal cancer. Oncologist 6:17-23, 2001 (suppl 4)
23. Rougier P, Mitry E: Review of the role of CPT-11 in the treatment of colorectal cancer. Clin Colorectal Cancer 1:87-94, 2001
24. Benson AB, Goldberg RM: Optimal use of the combination of irinotecan and 5-fluorouracil. Semin Oncol 30:68-77, 2003 (suppl 6)
25. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
26. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
27. Glimelius B, Risatmaki R, Kjaer M, et al: Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 13:1868-1873, 2002
28. Bouzid K, Khalfallah S, Tujakowski J, et al: A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 14:1106-1114, 2003
29. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-145, 2001
30. Van Cutsem E, Douillard JY, Köhne C-H: Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 345:1351-1352, 2001
31. Vanhoefer U, Harstrick A, Köhne C-H, et al: Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17:907-913, 1999
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
34. Köhne C-H, Cunningham D, Di Costanzo CF, et al: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 13:308-317, 2002
35. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
36. Schöffski P, Lutz MP, Folprecht G, et al: Cetuximab (C225) plus irinotecan (CPT-11 ) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21:159a, 2002 (abstr 633)